

K981601

JUL 28 1998

Summary of Safety and Effectiveness

DETERMINATION OF SUBSTANTIAL EQUIVALENCE

The California Medical Laboratories, Inc. devices are substantially equivalent to the DLP and Research Medical predicate device. The California Medical Laboratories, Inc. devices have substantially equivalent intended uses as the predicate device. The California Medical Laboratories, Inc. devices have technologic characteristics which are substantially equivalent to the DLP and Research Medical predicate device.

COMPANY AND CONTACT PERSON

California Medical Laboratories Inc.
2681 Kelvin Avenue
Irvine, California 92614

Mehmet Bicakci
President

DEVICE NAME

California Medical Laboratories Inc. Malleable Vent Catheter

NAME OF PREDICATE OR LEGALLY MARKETED DEVICE

The claim of substantial equivalence is based upon the following devices:

- Research Medical, Inc. Left Ventricular Vent Catheter
- DLP, Inc. Left Ventricular Malleable Vent Catheter

DESCRIPTION OF DEVICE

The Malleable Vent Catheter is designed to vent/drain the left ventricular during coronary artery bypass surgery.

It consists of soft polyvinyl chloride (PVC) tubing with a radius tip and vent holes 3.5 cm along the distal tip. The soft PVC tubing consists of two lumens; one large lumen for venting/drainage and one smaller lumen which encapsulates the stainless steel wire. The encapsulated stainless steel wire enables reshaping of the catheter prior to insertion and support during catheter placement. The proximal end of the catheter contains a rigid PVC connector and depth markings along the large lumen.

STATEMENT OF INTENDED USE

The Malleable Vent Catheter is intended for use during cardiopulmonary bypass Surgery to vent/drain the left ventricle.

STATEMENT OF INTENDED USE OF PREDICATE/MARKETED DEVICES

The predicate devices have the same intended use as stated above.

STATEMENT OF COMPARISON OF TECHNOLOGIC CHARACTERISTICS BETWEEN DEVICE AND PREDICATE DEVICE

The California Medical Laboratories, Inc devices have technologic characteristics which are substantially equivalent to the predicate device.



JUL 28 1998

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. Mehmet Bicakci
President
California Medical Laboratories, Inc.
2681 Kelvin Avenue
Irvine, CA 92614

Re: K981601
Malleable Vent Catheter
Regulatory Class: II (Two)
Product Code: DWF
Dated: May 1, 1998
Received: May 4, 1998

Dear Mr. Bicakci:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Pre-market Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your pre-market notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 - Mr. Mehmet Bicakci

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,



Thomas J. Callahan, Ph.D.
Director
Division of Cardiovascular, Respiratory,
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known): K981601

Device Name: California Medical Laboratories Inc. Malleable Vent Catheter.

Indications For Use: The Malleable Vent Catheter is indicated for use during cardiopulmonary bypass surgery to vent/drain the left ventricle.

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)
Division of Cardiovascular, Respiratory,
and Neurological Devices

510(k) Number K981601

Prescription Use X
Per 21 CFR 801.109

OR Over-The-Counter Use _____